Ophthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, October 31, 2018

October 23, 2018

NEW YORK–(BUSINESS WIRE)–Oct. 23, 2018– Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2018 financial and operating results on Wednesday, October 31, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

To participate in this conference call, dial 888-204-4368 (USA) or 323-994-2082 (International), passcode 3714524. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: www.ophthotech.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is 888-203-1112 (USA Toll Free), passcode 3714524.

About Ophthotech Corporation

Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. For more information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech’s views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.

OPHT-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005229/en/

Source: Ophthotech Corporation

Investors

Kathy Galante

Ophthotech Corporation

Vice President, Investor Relations and Corporate Communications

212-845-8231

kathy.galante@ophthotech.com

or

Media

Alex Van Rees

SmithSolve LLC on behalf of Ophthotech Corporation

973-442-1555 ext. 111

alex.vanrees@smithsolve.com